Therapeutic Trial of EPI -743 In Patients With Disorders of Energy Utilization or Oxidation-Reduction
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Vatiquinone (Primary)
- Indications Metabolic disorders; Mitochondrial disorders
- Focus Therapeutic Use
- 25 Sep 2019 Status changed from active, no longer recruiting to completed.
- 24 Oct 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2021.
- 24 Oct 2018 Planned primary completion date changed from 31 Oct 2018 to 1 Jan 2021.